Get the Stockscreener App
34.49
4.12%
-1.5075
Tyra Biosciences Inc stock is traded at $34.49, with a volume of 218.65K.
It is down -4.12% in the last 24 hours and up +23.32% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
See More
Previous Close:
$36.00
Open:
$36.04
24h Volume:
218.65K
Relative Volume:
0.27
Market Cap:
$1.86B
Revenue:
-
Net Income/Loss:
$-119.95M
P/E Ratio:
-17.14
EPS:
-2.0123
Net Cash Flow:
$-95.28M
1W Performance:
-1.49%
1M Performance:
+23.32%
6M Performance:
+175.70%
1Y Performance:
+221.39%
1-Day Range:
$34.45
$36.96
1-Week Range:
$33.20
$36.96
52-Week Range:
$6.42
$36.96
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
34.48 | 1.94B | 0 | -119.95M | -95.28M | -2.0123 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.45 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.27 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
695.16 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.18 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.49 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-26 | Initiated | William Blair | Outperform |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-21-25 | Resumed | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | UBS | Buy |
| Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-15-24 | Initiated | Piper Sandler | Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
Tyra Biosciences stock hits all-time high at 36.69 USD - Investing.com
ACMG meeting attendance advances FGFR3 inhibition work, Tyra Biosciences outlines - Traders Union
Tyra Biosciences (NASDAQ:TYRA) Sets New 12-Month HighHere's What Happened - MarketBeat
Trading the Move, Not the Narrative: (TYRA) Edition - Stock Traders Daily
Assessing Tyra Biosciences (TYRA) Valuation After Wider Full Year Loss And Earnings Update - Sahm
TD Cowen Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - 富途牛牛
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Technicals: Is Tyra Biosciences Incs ROE strong enoughQuarterly Earnings Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Update Recap: Is Tyra Biosciences Inc a strong candidate for buy and holdJuly 2025 Macro Moves & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing Tyra Biosciences (TYRA) Valuation After William Blair Coverage And Dabogratinib Progress - Sahm
Is Tyra Biosciences Inc stock undervalued right nowJuly 2025 Closing Moves & Growth Focused Stock Reports - baoquankhu1.vn
HC Wainwright Issues Optimistic Forecast for TYRA Earnings - Defense World
Tyra Biosciences stock reaches all-time high at 35.75 USD - Investing.com Nigeria
HC Wainwright Boosts Earnings Estimates for Tyra Biosciences - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year HighHere's Why - MarketBeat
Growth Stocks To Keep An Eye On – March 3rd - Defense World
Tyra Bioscience Raises $126 Million in Block Share Sale - TipRanks
Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com Australia
Tyra Biosciences announces $126 million stock sale in block transaction By Investing.com - Investing.com Nigeria
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), biotechnology company Tyra Biosciences has reached an agreement to privately issue 4 million common shares to a major investment management firm. - Bitget
Tyra Biosciences agreed to issue 4 million shares at $31.50 per share to a large investment management firmSEC filing - marketscreener.com
Tyra Biosciences Agreed To Issue 4 Million Shares At $31.50 Per Share To A Large Investment Management FirmSEC Filing - TradingView
Tyra Bios to sell 4.0M shares at $31.50 in $126M ATM block transaction - TradingView
Tyra Biosciences stock reaches all-time high at 35.75 USD By Investing.com - Investing.com Canada
Tyra Biosciences (NASDAQ:TYRA) Shares Down 6.4%Here's What Happened - MarketBeat
TYRA: Oral Dabogratinib targets blockbuster potential in UTUC, NMIBC, and achondroplasia with pivotal data ahead - TradingView
TYRA: Oral dabogratinib targets blockbuster opportunities in UTUC, NMIBC, and achondroplasia - TradingView
Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative? - Yahoo Finance
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy By Investing.com - Investing.com Canada
TYRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tyra Biosciences Q4 Loss Widens - marketscreener.com
Tyra Biosciences 10-K: Net loss $119.95M, EPS $(2.01) - TradingView
Tyra Biosciences (NASDAQ: TYRA) maps FGFR oncology and achondroplasia pipeline - Stock Titan
Tyra Biosciences (Nasdaq: TYRA) boosts R&D and outlines 2026 trial catalysts - Stock Titan
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - PR Newswire
Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data - MarketBeat
TYRATyra Biosciences, Inc. Latest Stock News & Market Updates - Stock Titan
Nasdaq Moves: What are the risks of holding Tyra Biosciences Inc2025 Market WrapUp & Stepwise Trade Execution Plans - baoquankhu1.vn
TYRA SEC FilingsTyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Tyra Biosciences (TYRA) Valuation Under Review After ASCO Catalysts And Positive Analyst Attention - simplywall.st
Aug Swings: Is Tyra Biosciences Inc stock undervalued right nowMarket Risk Report & Scalable Portfolio Growth Methods - baoquankhu1.vn
CEO Change: Is Tyra Biosciences Inc stock undervalued right nowPortfolio Growth Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
TYRA Should I Buy - Intellectia AI
Tyra Biosciences, Inc. (TYRA) Stock Analysis: 48.56% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
(TYRA) Volatility Zones as Tactical Triggers - Stock Traders Daily
TYRA: Phase II trials for dabogratinib target NMIBC, UTUC, and achondroplasia, with key data due this year - TradingView
TYRA: FGFR3-targeted trials advance in NMIBC, achondroplasia, and UTUC, with key data expected this year - TradingView
Tyra Biosciences (TYRA) Price Target Increased by 14.97% to 48.96 - Nasdaq
ASCO-GU 2026: Key Oncology Updates From VIR, TARA, TYRA And Others - RTTNews
Tyra Biosciences stock hits all-time high at 34.0 USD - Investing.com India
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tyra Biosciences Inc Stock (TYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bensen Daniel | Chief Discovery Officer |
Feb 12 '26 |
Sale |
32.87 |
8,000 |
262,965 |
146,981 |
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):